#USA #Boston #Huntington's Disease #Skyhawk Therapeutics #SKY-0515

Skyhawk Therapeutics Unveils 15-Month Study Findings for SKY-0515 in Huntington's Disease

In a major development for Huntington's Disease research, Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company, has disclosed the final results of its Phase 1/2 clinical trial for SKY-0515, an oral treatment candidate aimed at addressing this devastating neurodegenerative condition. After 15 months of evaluation, the data reveals promising outcomes, indicating significant improvements for patients receiving treatment.

Key Findings

The clinical trial involved a rigorous assessment of SKY-0515's efficacy. At the primary evaluation mark, patients treated with SKY-0515 had a statistically significant improvement in their composite score on the composite unified Huntington's Disease Rating Scale (cUHDRS). Specifically, an increase of +1.59 points was noted in those receiving the treatment, contrasting with a decline of -0.65 points in the control group drawn from an external natural history database. This difference highlights the potential effectiveness of SKY-0515 as a therapeutic option for patients with Huntington's Disease (HD).

The trial also meticulously analyzed four essential components of the cUHDRS – motor score, functional capacity, symbol digit modalities test, and Stroop Word Reading Test. Results consistently favored SKY-0515, demonstrating improvements across all measured outcomes. For example, the average functional capacity score saw an improvement of +0.98 points, and motor scores improved marginally, suggesting enhanced daily functioning for patients.

Biological Impact

Beyond symptomatic improvements, SKY-0515 has shown a substantial reduction in the mutant huntingtin protein levels, decreasing more than 60% in patients taking the 9 mg dosage, alongside a 25% reduction in PMS1 mRNA. Targeting these proteins is crucial, as the mutant huntingtin protein is the primary contributor to the pathology of Huntington's Disease.

Dr. Samuel Frank, a key opinion leader in Huntington's research, remarked on the significance of these findings, noting that the 1.59-point difference in clinical measurements is precisely what the scientific community aims to achieve with effective therapeutic agents. The results underscore the dual targeting mechanism of SKY-0515, which could lead to groundbreaking advancements in treatment for those afflicted with Huntington's Disease.

Trial Structure and Methodology

The Phase 1/2 trial was designed as a multi-centered, randomized, double-blind, placebo-controlled study focusing primarily on safety and efficacy. Conducted over 15 months, all participants initially received either a placebo or one of two doses of SKY-0515 (4 mg or 9 mg) for a twelve-week blinded period, followed by an extended treatment phase. Notably, the majority of patients received the higher 9 mg dose, which evidently yielded superior results.

Patients receiving SKY-0515 demonstrated consistent improvements at various evaluation points throughout the 15 months, maintaining functional scores above their baseline levels while control group scores declined after the six-month mark. This suggests a long-term benefit that patterns the benefits seen in the clinical outcomes.

Next Steps

Currently, the SKY-0515 program is advancing towards a pivotal global Phase 2/3 study named FALCON-HD, which aims to further substantiate these findings with more than 200 patients across multiple clinical sites globally. With your continued commitment to research, Skyhawk aims to validate the efficacy and safety of SKY-0515, touting a treatment that is simple to administer — a once-daily oral pill that patients can take at home.

Katie Jackson, Executive Director of Help 4 HD International, reflects on the profound impact such advancements may have on the Huntington's community, pointing out the importance of accessible treatments, especially for families unable to seek specialized care. Jackson expressed hope that the ongoing research may pave the way for a more hopeful future for families affected by Huntington's Disease.

Conclusion

In summary, SKY-0515 demonstrates significant promise as a potential treatment for Huntington's Disease. The findings from the Phase 1/2 trial present essential insights that reinforce hope for patients facing this challenging illness. Future results from the ongoing Phase 2/3 study will be crucial in determining the viability of this novel therapy, and with the involvement of Skyhawk Therapeutics in advancing treatment options, the patient community anticipates a brighter future. As the world watches, the commitment to finding effective treatments continues to be a beacon of hope against Huntington's Disease.